Last checked at 15 Mar 2017 09:33
ValiRx Plc
("ValiRx" or "the Company")
PDMR / Director Dealing
London, UK., 15 March 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received the following notifications from PDMRs of dealings in the Company's shares, all of which related to the issue of shares announced on 2 March 2017 for which Admission to trading on AIM occurred on 15 March 2017.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Satu Vainikka | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/ Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ValiRx Plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | |||||
Identification code | GB00BWWYSP41 | |||||
b) | Nature of the transactions | Issue of Ordinary Shares | ||||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
2.50 p | 400,000 | |||||
d) | Aggregated information | |||||
- Aggregated volume | 400,000 | |||||
- Price | 2.50 p | |||||
e) | Date of the transaction | 15 March 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | George Morris | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Operating Officer | ||||
b) | Initial notification/ Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ValiRx Plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | |||||
Identification code | GB00BWWYSP41 | |||||
b) | Nature of the transactions | Issue of Ordinary Shares | ||||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
2.50 p | 400,000 | |||||
d) | Aggregated information | |||||
- Aggregated volume | 400,000 | |||||
- Price | 2.50 p | |||||
e) | Date of the transaction | 15 March 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Gerry Desler | ||||
2 | Reason for the notification | |||||
a) | Position/status | Finance Director | ||||
b) | Initial notification/ Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ValiRx Plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument | |||||
Identification code | GB00BWWYSP41 | |||||
b) | Nature of the transactions | Issue of Ordinary Shares | ||||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
2.50 p | 400,000 | |||||
d) | Aggregated information | |||||
- Aggregated volume | 400,000 | |||||
- Price | 2.50 p | |||||
e) | Date of the transaction | 15 March 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Dr Satu Vainikka, Chief Executive | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Mark Treharne, Corporate Development Manager | Tel: +44 (0) 7736 564 686 mark.treharne@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0) 20 7213 0880 |
Liam Murray / Jo Turner | |
Beaufort Securities Limited (Joint Broker) | Tel: +44 (0) 207 382 8300 |
Jon Belliss | |
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.